|Other Names||Mitogen-activated protein kinase kinase kinase 14, NF-kappa-beta-inducing kinase, HsNIK, Serine/threonine-protein kinase NIK, MAP3K14, NIK|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7967c was selected from the Center region of human NIK . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. Promotes proteolytic processing of NFKB2/P100, which leads to activation of NF-kappa-B via the non- canonical pathway. Could act in a receptor-selective manner.|
|Tissue Location||Weakly expressed in testis, small intestine, spleen, thymus, peripheral blood leukocytes, prostate, ovary and colon.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NIK (mitogen-activated protein kinase kinase kinase 14), a member of the Ser/Thr protein kinase family, binds to TRAF2 and stimulates NF-kappaB activity. It shares sequence similarity with several other MAPKK kinases. It participates in an NF-kappaB-inducing signalling cascade common to receptors of the tumour-necrosis/nerve-growth factor (TNF/NGF) family and to the interleukin-1 type-I receptor.
Andreakos, E., et al., Blood 101(3):983-991 (2003).Ninomiya-Tsuji, J., et al., Nature 398(6724):252-256 (1999).Aronsson, F.C., et al., Hum. Genet. 103(3):340-345 (1998).Lin, X., et al., Mol. Cell. Biol. 18(10):5899-5907 (1998).Malinin, N.L., et al., Nature 385(6616):540-544 (1997).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.